Medivir AB - Interim Report January - June 2018
During the second quarter of 2018, Medivir continued the rigorous development and advancement of our projects.
- During the second quarter of 2018, Medivir continued the rigorous development and advancement of our projects.
- Top-line results from the phase IIa extension study with MIV-711 in osteoarthritis were announced at the end of the second quarter.
- The information in this report comprises the information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation.
- The information was submitted for publication, through the agency of the contact persons set out above, at 08.45 CET on 25 July 2018.